Physician profile
Charles D Chipman
NPI 1487655494
$9,475.27
in general payments reported to CMS, 2019-2025
55 companies · $22.96 in 2025
The $22.96 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $1,282 · 2021: $1,918 · 2022: $1,819 · 2023: $1,979 · 2024: $1,705 · 2025: $22.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,707.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,416.43 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,125.15 | 2019-2024 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $726.36 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $541.84 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $510.91 | 2019-2024 | |
| Amgen INC. | $425.47 | 2019-2024 | Repatha, Otezla, Prolia |
| Astellas Pharma US INC | $363.85 | 2019-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $356.11 | 2019-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $335.70 | 2022-2024 | |
| Pfizer INC. | $326.09 | 2019-2024 | |
| Amarin Pharma, INC. | $278.04 | 2019-2022 | |
| Eisai INC. | $273.38 | 2020-2022 | |
| Glaxosmithkline, LLC. | $187.55 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $186.62 | 2020-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.40 | 2019-2024 | Jardiance |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Chipman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.